IQV Add to watchlist $178.10 +2.82 (+1.61%) Last updated: Apr 16, 2026 00:46
52-Week Range
$178.10
$134.65 $178.10 $247.05

Fundamentals Overview

IQVIA Holdings Inc. is in the middle of its 52-week range with moderate valuation, trading relatively flat today.

Valuation moderate

P/E 22.5 P/B 4.66 P/S 1.85

Intrinsic value (DCF)

+37.2% upside vs price

Profitability

Net margin 8.3%

Risk (Beta)

1.39 — higher vol

Earnings & growth

EPS $7.91 Rev +6.4% Profit +55.3% vs prior qtr

BullzEye Analysis

Our composite tilts Hold on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.

Composite Signal

Sell
Buy
Hold — 52% confidence Risk: High Volatility — Beta 1.39. Consider smaller position size due to higher beta.

Supporting (Buy):

DCF +37.2% upside vs price · Analyst grade: B+ · Sentiment improving (5 upgrades)

Pressures (Sell):

3M vs S&P 500: -26.7% · 3M vs Healthcare sector: -20% · Beta 1.39 (elevated)

Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.

Key Stats

Market Cap
$30.22B
P/E (TTM)
22.51
EPS (TTM)
$7.91
Dividend Yield
N/A
52-Week Range
$134.65 - $247.05
Volume vs Avg
N/A
Beta
1.39

About

IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life scienc...
Sector: Healthcare
Headquarters: US
Employees: 89,000
IPO Date: May 2013
Website: www.iqvia.com
Beta: 1.39 (More volatile than market)

Ratings & Grades at a Glance

Overall rating: B+. Recent institutional grades: majority upgrades. Current institutional positions: Buy: 14, Equal Weight: 3, Hold: 2, Neutral: 3, Outperform: 4, Overweight: 4.

Financial story & AI narrative

Open this tab to load the financial story.

Valuation & Ratios

Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.

DCF vs price: DCF estimate is $244.29; current price is $178.10. That’s a +37.2% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.

Metric Value
Valuation
P/E (TTM) 22.51
DCF value (model) $244.29 (37.2% upside)
PEG (TTM) N/A
P/B (TTM) 4.66
P/S (TTM) 1.85
P/FCF (TTM) 12.19
Liquidity & enterprise
Current Ratio (TTM) 0.75
Quick Ratio (TTM) 0.75
Cash Ratio (TTM) 0.24
Profitability
ROE (TTM) N/A
ROA (TTM) N/A
Revenue growth (YoY) N/A
Net margin (TTM) 8.34%
Gross margin (TTM) 26.28%
Operating margin (TTM) 14.02%
Debt to equity (TTM) N/A

Latest News

News loads when you open this tab.

Price Target, Ratings & Grades

Analyst price targets, consensus, rating snapshot, and institutional grades for IQV.

Analyst Sentiment at a Glance

B+ Sentiment Improving
Buy 14Equal Weight 3Hold 2Neutral 3Outperform 4Overweight 4
5 upgrades, 1 downgrade
Price Target Consensus
Current $178.10
Median $240.00
Consensus $229.22
Low consensus $185.00
High consensus $258.00

Stock Grades (Institutions)

Institution Action Previous Grade New Grade Date
Evercore ISI Group maintain Outperform Outperform 2026-04-08
TD Cowen upgrade Hold Buy 2026-03-09
Barclays upgrade Equal Weight Overweight 2026-03-06
Truist Securities maintain Buy Buy 2026-02-19
Stifel maintain Buy Buy 2026-02-06
JP Morgan maintain Overweight Overweight 2026-02-06
Citigroup maintain Neutral Neutral 2026-02-06
Barclays maintain Equal Weight Equal Weight 2026-02-06
Jefferies maintain Buy Buy 2026-02-06
UBS maintain Buy Buy 2026-02-06
TD Cowen maintain Hold Hold 2026-01-22
Truist Securities maintain Buy Buy 2026-01-08
UBS maintain Buy Buy 2026-01-08
Morgan Stanley maintain Overweight Overweight 2025-12-02
TD Cowen downgrade Buy Hold 2025-11-03
Stifel maintain Buy Buy 2025-10-29
Baird upgrade Neutral Outperform 2025-10-29
JP Morgan maintain Overweight Overweight 2025-10-29
UBS maintain Buy Buy 2025-10-29
Truist Securities maintain Buy Buy 2025-10-29
Citigroup maintain Neutral Neutral 2025-10-29
HSBC upgrade Hold Buy 2025-10-09
Evercore ISI Group maintain Outperform Outperform 2025-10-08
Barclays maintain Equal Weight Equal Weight 2025-10-02
Jefferies upgrade Hold Buy 2025-09-09
Mizuho maintain Outperform Outperform 2025-07-25
Truist Securities maintain Buy Buy 2025-07-23
Citigroup maintain Neutral Neutral 2025-07-23
Barclays maintain Equal Weight Equal Weight 2025-07-23
UBS maintain Buy Buy 2025-07-23